Literature DB >> 24619623

Hughes syndrome/APS. 30 years on, what have we learnt? Opening talk at the 14th International Congress on antiphospholipid antibodies Rio de Janiero, October 2013.

Graham R V Hughes1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24619623     DOI: 10.1177/0961203314522341

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


× No keyword cloud information.
  5 in total

1.  Autonomic neuropathy-in its many guises-as the initial manifestation of the antiphospholipid syndrome.

Authors:  Jill R Schofield
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

2.  Presence of Immune Complexes of IgG/IgM Bound to B2-glycoprotein I Is Associated With Non-criteria Clinical Manifestations in Patients With Antiphospholipid Syndrome.

Authors:  Dolores Pérez; Ljudmila Stojanovich; Laura Naranjo; Natasa Stanisavljevic; Gordana Bogdanovic; Manuel Serrano; Antonio Serrano
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

3.  Immune Complexes of Beta-2-Glycoprotein I and IgA Antiphospholipid Antibodies Identify Patients With Elevated Risk of Thrombosis and Early Mortality After Heart Transplantation.

Authors:  Manuel Serrano; Laura Morán; Jose Angel Martinez-Flores; Esther Mancebo; Daniel Pleguezuelo; Oscar Cabrera-Marante; Juan Delgado; Antonio Serrano
Journal:  Front Immunol       Date:  2019-12-23       Impact factor: 7.561

4.  Avidity of anti-phospholipid antibodies in relation to their levels.

Authors:  Lenka FialovÁ; Oliver KuchaŘ; Milada PetrÁČkovÁ; Ivan Malbohan; TomÁŠ Zima
Journal:  Cent Eur J Immunol       Date:  2020-07-27       Impact factor: 2.085

5.  Incidence of thromboembolic events in asymptomatic carriers of IgA anti ß2 glycoprotein-I antibodies.

Authors:  Carlos Tortosa; Oscar Cabrera-Marante; Manuel Serrano; José A Martínez-Flores; Dolores Pérez; David Lora; Luis Morillas; Estela Paz-Artal; José M Morales; Daniel Pleguezuelo; Antonio Serrano
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.